Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.48 |
| ▸ | NOS3 | P29474 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13955039 | 0.86 | NOS1 (0.43) | NOS1NOS3AURKATYK2JAK2 | |
| SCHEMBL22596444 | 0.75 | NOS3 (0.34) | NOS1NOS3L3MBTL1 | |
| SCHEMBL6616471 | 0.75 | HTR2C (0.44) | NOS1NOS3HTR2CHTR2B | |
| SCHEMBL16854923 | 0.73 | NOS3 (0.48) | NOS1NOS3MEN1MAPTBRCA1 | |
| SCHEMBL15919925 | 0.73 | NOS3 (0.48) | NOS1NOS3MEN1MAPTBRCA1 | |
| SCHEMBL8561861 | 0.73 | NOS3 (0.48) | NOS1NOS3MEN1MAPTBRCA1 | |
| SCHEMBL18685321 | 0.72 | NOS3 (0.35) | NOS1NOS3L3MBTL1 | |
| SCHEMBL17679887 | 0.69 | PARP1 (0.34) | NOS1NOS3 | |
| SCHEMBL18535492 | 0.68 | HTR2A (0.37) | HTR2CHTR2B | |
| SCHEMBL19487774 | 0.68 | ALDH1A1 (0.32) | NOS1NOS3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | NOS1 2004/4885NOS3 2238/4885AURKA 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.